Loading
A phase 2 trial of Pembrolizumab in melanoma, run by Primmune Therapeutics, Inc., now recruiting.
The Efficacy and Safety of PRTX007-003 Combined With Pembrolizumab in Resectable Stage III Melanoma is a phase 2 interventional study registered as NCT07565285 by Primmune Therapeutics, Inc., with 48 participants planned, started 2026-07-01 and due to reach its primary completion in 2027-12. Interventions recorded: PRTX007, Pembrolizumab. Conditions listed: Melanoma Stage III. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Stage III melanoma (after surgery), Melanoma, Pembrolizumab, Immune checkpoint inhibitors.
Shares Stage III melanoma (after surgery), Melanoma, Pembrolizumab, Immune checkpoint inhibitors.
Shares Stage III melanoma (after surgery), Melanoma, Pembrolizumab, Immune checkpoint inhibitors.
Shares Stage III melanoma (after surgery), Melanoma, Pembrolizumab.
Shares Stage III melanoma (after surgery), Melanoma, Pembrolizumab, Immune checkpoint inhibitors.
Shares Stage III melanoma (after surgery), Melanoma, Pembrolizumab, Immune checkpoint inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/